The invention belongs to the field of biological medicines, and discloses an application of a VPS35 inhibitor in preparation of
Zika virus infection resistant drugs, the VPS35 inhibitor comprises at least one of the following two substances: I: a substance for inhibiting VPS35
gene expression in host cells; and II: a substance for inhibiting the retrograde transport function of the VPS35
protein in the host
cell. The invention finds that the VPS35
protein is an important
host factor of the replication period of the
Zika virus for the first time, and a
Zika virus infection
model system verifies that the replication of the Zika
virus in the host
cell can be inhibited by inhibiting the expression of the VPS35
gene in the host
cell or inhibiting the retrograde transport function of the VPS35
protein. Compared with traditional drugs targeting Zika
virus protein, the VPS35 inhibitor provided by the invention targets
host factors, is more difficult to induce Zika
virus drug resistance, and has more lasting treatment potential.